Physician profile
Thomas D Long
NPI 1316901093
$7,800.84
in general payments reported to CMS, 2019-2025
41 companies · $766 in 2025
The $766 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $775 · 2021: $1,480 · 2022: $1,298 · 2023: $1,288 · 2024: $985 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,038.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,705.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $804.00 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $729.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $565.09 | 2019-2024 | |
| Glaxosmithkline, LLC. | $492.13 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $488.44 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $411.47 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $360.56 | 2019-2022 | |
| Amarin Pharma, INC. | $240.19 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.11 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $161.84 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $157.49 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $138.52 | 2023-2025 | Rexulti, Nuedexta |
| Sanofi-Aventis U.S. LLC | $127.22 | 2019-2022 | |
| Amgen INC. | $111.49 | 2019-2024 | Krystexxa |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.